- Home
- MFIN vs CHRS Comparison
MFIN vs CHRS Comparison
Compare MFIN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- CHRS
- Stock Information
- Founded
- MFIN 1995
- CHRS 2010
- Country
- MFIN United States
- CHRS United States
- Employees
- MFIN N/A
- CHRS N/A
- Industry
- MFIN Finance: Consumer Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- CHRS Health Care
- Exchange
- MFIN Nasdaq
- CHRS Nasdaq
- Market Cap
- MFIN 190.0M
- CHRS 191.3M
- IPO Year
- MFIN 1996
- CHRS 2014
- Fundamental
- Price
- MFIN $9.32
- CHRS $1.39
- Analyst Decision
- MFIN
- CHRS Strong Buy
- Analyst Count
- MFIN 0
- CHRS 4
- Target Price
- MFIN N/A
- CHRS $5.38
- AVG Volume (30 Days)
- MFIN 48.0K
- CHRS 2.0M
- Earning Date
- MFIN 02-18-2025
- CHRS 03-12-2025
- Dividend Yield
- MFIN 4.75%
- CHRS N/A
- EPS Growth
- MFIN N/A
- CHRS N/A
- EPS
- MFIN 1.69
- CHRS N/A
- Revenue
- MFIN $293,257,000.00
- CHRS $304,340,000.00
- Revenue This Year
- MFIN N/A
- CHRS $2.47
- Revenue Next Year
- MFIN $10.95
- CHRS N/A
- P/E Ratio
- MFIN $5.47
- CHRS N/A
- Revenue Growth
- MFIN 18.48
- CHRS 44.19
- 52 Week Low
- MFIN $6.48
- CHRS $0.66
- 52 Week High
- MFIN $10.50
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- MFIN 47.14
- CHRS 45.86
- Support Level
- MFIN $8.74
- CHRS $1.38
- Resistance Level
- MFIN $9.52
- CHRS $1.60
- Average True Range (ATR)
- MFIN 0.28
- CHRS 0.13
- MACD
- MFIN -0.01
- CHRS -0.03
- Stochastic Oscillator
- MFIN 62.37
- CHRS 9.52
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.